Barclays’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-105
| Closed | -$1.19K | – | 5499 |
|
|
2023
Q4 | $1.19K | Buy |
+105
| New | +$825 | ﹤0.01% | 5105 |
|
|
2023
Q3 | – | Sell |
-3,379
| Closed | -$24K | – | 4777 |
|
|
2023
Q2 | $24K | Buy |
3,379
+2,703
| +400% | +$18.7K | ﹤0.01% | 4096 |
|
|
2023
Q1 | $5.03K | Buy |
676
+60
| +10% | +$505 | ﹤0.01% | 4825 |
|
|
2022
Q4 | $4.47K | Sell |
616
-827
| -57% | -$6.97K | ﹤0.01% | 5012 |
|
|
2022
Q3 | $14K | Hold |
1,443
| – | – | ﹤0.01% | 4195 |
|
|
2022
Q2 | $28K | Sell |
1,443
-304
| -17% | -$7.87K | ﹤0.01% | 4279 |
|
|
2022
Q1 | $88K | Sell |
1,747
-1,966
| -53% | -$102K | ﹤0.01% | 3849 |
|
|
2021
Q4 | $281K | Buy |
3,713
+596
| +19% | +$40.7K | ﹤0.01% | 3444 |
|
|
2021
Q3 | $246K | Sell |
3,117
-494
| -14% | -$49.7K | ﹤0.01% | 3516 |
|
|
2021
Q2 | $500K | Buy |
3,611
+1,902
| +111% | +$363K | ﹤0.01% | 3075 |
|
|
2021
Q1 | $358K | Buy |
1,709
+37
| +2% | +$7.42K | ﹤0.01% | 3392 |
|
|
2020
Q4 | $277K | Buy |
1,672
+190
| +13% | +$29.4K | ﹤0.01% | 3585 |
|
|
2020
Q3 | $252K | Sell |
1,482
-828
| -36% | -$119K | ﹤0.01% | 3695 |
|
|
2020
Q2 | $383K | Buy |
2,310
+889
| +63% | +$139K | ﹤0.01% | 3558 |
|
|
2020
Q1 | $164K | Buy |
1,421
+199
| +16% | +$28K | ﹤0.01% | 4455 |
|
|
2019
Q4 | $180K | Buy |
1,222
+569
| +87% | +$86.3K | ﹤0.01% | 5118 |
|
|
2019
Q3 | $89K | Buy |
653
+271
| +71% | +$38.1K | ﹤0.01% | 5566 |
|
|
2019
Q2 | $50K | Buy |
382
+306
| +403% | +$35.6K | ﹤0.01% | 6100 |
|
|
2019
Q1 | $7K | Buy |
+76
| New | +$9.99K | ﹤0.01% | 6653 |
|
Barclays's HARP Position: Q1 2024 in Review
Barclays sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q1 2024, closing a stake of 105 shares — an estimated $1.19K sold.
Barclays first reported a position in HARP in Q1 2019 and held it in 19 quarters. The position peaked at $500K in Q2 2021. 0 funds tracked by Wall St. Rank hold HARP as of Q1 2024.
- Barclays reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Barclays sold 105 Harpoon Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.19K.
- Barclays first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2019 and held it in 19 quarters.
- Barclays's Harpoon Therapeutics, Inc. Common Stock position peaked at $500K in Q2 2021.
- 0 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Barclays's 13F filing for Q1 2024, filed 15 May 2024.